Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 15/20 | 1.00 |
| ▸ | ESR2 | Q92731 | 15/20 | 1.00 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.77 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.55 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3932748 | 0.87 | ESR1 (1.00) | ESR1ESR2HSP90AA1 | |
| SCHEMBL14261867 | 0.83 | ESR1 (0.72) | ESR1ESR2HSP90AA1MEN1CYP2C9 | |
| SCHEMBL3922605 | 0.83 | ESR1 (1.00) | ESR1ESR2HSP90AA1 | |
| SCHEMBL4933777 | 0.82 | ESR1 (0.69) | ESR1ESR2HSP90AA1KDM4EMEN1 | |
| SCHEMBL21889293 | 0.80 | ESR1 (0.69) | ESR1ESR2HSP90AA1 | |
| SCHEMBL7548059 | 0.79 | ESR1 (0.66) | ESR1ESR2HSP90AA1 | |
| SCHEMBL3929820 | 0.77 | ESR1 (1.00) | ESR1ESR2HSP90AA1 | |
| SCHEMBL4933522 | 0.76 | ESR1 (0.72) | ESR1ESR2HSP90AA1 | |
| SCHEMBL3927438 | 0.75 | ESR1 (0.77) | ESR1ESR2HSP90AA1 | |
| SCHEMBL5992116 | 0.75 | ESR1 (0.59) | ESR1ESR2HSP90AA1MEN1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080070960-A1 | Novel 3-Aryl-1,2-Benzisoxazole Derivatives and Use Thereof as Medicinal Products Against Cancer | AVENTIS PHARMA S.A. (FR) | 2008-03-20 | — | — | US | claimed |
| US-20080070960-A1 | Novel 3-Aryl-1,2-Benzisoxazole Derivatives and Use Thereof as Medicinal Products Against Cancer | AVENTIS PHARMA S.A. (FR) | 2008-03-20 | — | — | US | disclosed |
| US-20080070960-A1 | Novel 3-Aryl-1,2-Benzisoxazole Derivatives and Use Thereof as Medicinal Products Against Cancer | AVENTIS PHARMA S.A. (FR) | 2008-03-20 | — | — | US | disclosed |
| US-20080070960-A1 | Novel 3-Aryl-1,2-Benzisoxazole Derivatives and Use Thereof as Medicinal Products Against Cancer | AVENTIS PHARMA S.A. (FR) | 2008-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070960-A1 | Novel 3-Aryl-1,2-Benzisoxazole Derivatives and Use Thereof as Medicinal Products Against Cancer | UGT2B7, UGT2B17, CYP4X1 | ESR1 2306/4885ESR2 987/4885HSP90AA1 1416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.